Pfizer’s analysis partnership with Sangamo Therapeutics produced a hemophilia A gene remedy that reached FDA discussions a couple of regulatory submission. That’s so far as the alliance will go. Pfizer is terminating the seven-year-old pact, a transfer that comes earlier than the pharmaceutical big should pay pricey milestone funds for a product with unsure business prospects.
In keeping with Sangamo, Pfizer stated the termination displays its resolution to not go ahead with regulatory submissions for the hemophilia A gene remedy, giroctocogene fitelparvovec. The termination was introduced after Monday’s market shut. When the termination takes impact in April, Sangamo will regain all rights to the gene remedy. The Richmond, California-based biotech stated it nonetheless goals to advance this system and can discover all choices, together with in search of a brand new collaboration companion to take the remedy by means of regulatory overview and commercialization.
Giroctocogene fitelparvovec is a functioning model of the gene that codes for issue VIII, the clotting protein that’s poor in hemophilia A sufferers. The one-time remedy is meant to allow sufferers to supply issue VIII, bringing that protein nearer to regular ranges. Beneath the collaboration settlement signed in 2017, Sangamo was liable for Part 1/2 growth of the gene remedy. Pfizer’s duty spanned late-stage growth, regulatory submissions, and commercialization.
This previous summer time, Pfizer reported preliminary Part 3 outcomes displaying the gene remedy led to statistically vital reductions in annualized bleeding charges by means of 15 months. The pharma big stated it deliberate to satisfy with regulators. In keeping with Sangamo, Pfizer had stated it anticipated U.S. and European regulatory submissions would occur in early 2025. As lately as final month, Pfizer indicated it was discussing the info with regulators.
Hemophilia gene therapies have made it by means of regulatory overview. Pfizer did it earlier this yr, profitable FDA approval for Beqvez, a hemophilia B gene remedy that was licensed from Spark Therapeutics. However commercializing expensive hemophilia gene therapies has confirmed to be troublesome. For sufferers who can handle hemophilia with infusions of clotting proteins or power dosing of sure medication, one-time remedy from gene remedy has been a troublesome promote. Newer hemophilia medication are coming into the market, giving sufferers much more selections. Pfizer has one in all them with Hympavzi, a once-weekly injectable drug authorised by the FDA in October for each hemophilia A and B.
The commercialization challenges dealing with hemophilia gene therapies are forcing corporations to make arduous selections. Lackluster gross sales of Roctavian, a BioMarin Pharmaceutical gene remedy for hemophilia A authorised final yr, have led that firm to discover choices together with divestiture of the product. Now Pfizer has determined to not proceed with Sangamo’s hemophilia A gene remedy.
Beneath the gene remedy alliance, Sangamo acquired $70 million up entrance. In keeping with the biotech’s monetary reviews, it had acquired $55 million in milestone funds up to now. As much as $220 million in extra milestone funds remained excellent. Sangamo was relying on the Pfizer funds for its survival.
Collaborations with Novartis and Biogen ended final yr, main Sangamo to implement a company restructuring and layoffs. Sangamo has since inked offers with Genentech and Astellas Pharma, however these agreements include small upfront funds and milestones that could be years away. In its monetary reviews, Sangamo stated it has explored the potential of submitting for chapter safety. The corporate’s money place as of Sept. 30 was $39.2 million, in response to its report for the third quarter of 2024. Sangamo stated it anticipated to have sufficient money to final solely into the primary quarter of 2025.
Sangamo wants money to assist its pipeline of neurology genomic medicines, together with a gene remedy for Fabry illness. In October, the FDA confirmed to the corporate that Part 1/2 information can be adequate to assist a regulatory submission underneath the accelerated approval pathway. The corporate deliberate a submission for the second half of 2025.
Within the announcement of the Pfizer termination, Sangamo stated it believes it could actually chart a path ahead for its applications, however the firm acknowledged that extra funding is critical for advancing every of them, together with the hemophilia A gene remedy. In a ready assertion, Sangamo CEO Sandy Macrae stated the corporate was shocked and upset by Pfizer’s resolution to finish the collaboration so near the anticipated regulatory submissions.
“We’re dedicated to exploring the optimum path ahead for this vital remedy, together with in search of the correct companion with the main target and understanding of the genomic medication business setting to carry this medication to sufferers,” he stated.
Illustration: Kuzma, Getty Photos
